If you purchased shares of Prosensa Holding NV (NASDAQ:RNA)
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Prosensa Holding NV (NASDAQ:RNA)
Prosensa Holding NV reported that its annual Total Revenue declined from $8.69 million in 2011 to $7.85 million in 2012 while its respective Net Loss decreased from $11.58 million to $9.89 million. For the first quarter in 2013 Prosensa Holding NV reported quarterly Revenue of $2.4 million, compared to $1.97 million in the first quarter in 2012 and for the second quarter in 2013 Prosensa Holding NV reported quarterly Revenue of $1.98 million, compared to $1.25 million in 2012.
In June 2013 Prosensa Holding NV went public. Shares of Prosensa Holding NV (NASDAQ:RNA)
Then on Sept. 20, 2013, GlaxoSmithKline and Prosensa Holding NV announced that the Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6 Minute Walking Distance test compared to placebo.
Shares of Prosensa Holding NV (NASDAQ:RNA)
On Oct. 1, 2013, NASDA:RNA shares closed at $7.05 per share.
Those who purchased shares of Prosensa Holding NV have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.